Improved long-term glucose control in neonatal diabetes mellitus after early sulfonylurea allergy

Journal of Pediatric Endocrinology and Metabolism

Volumn 25, Issue 3-4, 2012, Pages 353-356

  Shah, Bina ^a   Breidbart, Emily ^a   Pawelczak, Melissa ^a   Lam, Leslie ^a   Kessler, Marion ^a   Franklin, Bonita ^a  

^a NEW YORK UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

neonatal diabetes; sulfonylurea

Indexed keywords

ADENOSINE TRIPHOSPHATE SENSITIVE POTASSIUM CHANNEL; GLIBENCLAMIDE; GLUCOSE; HEMOGLOBIN A1C; INSULIN; SULFONYLUREA; SULFONYLUREA RECEPTOR 1;

ALLERGY; ARTICLE; BLOOD GLUCOSE MONITORING; CASE REPORT; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; ERYTHEMA; FEMALE; GENE ACTIVATION; GENE MUTATION; GENETIC ANALYSIS; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPERGLYCEMIA; HYPOGLYCEMIA; MACULOPAPULAR RASH; NEWBORN; NEWBORN DIABETES MELLITUS; URTICARIA;

ATP-BINDING CASSETTE TRANSPORTERS; BLOOD GLUCOSE; CHILD; DIABETES MELLITUS; FEMALE; GLYBURIDE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; INFANT, NEWBORN; INSULIN; MUTATION; POTASSIUM CHANNELS, INWARDLY RECTIFYING; RECEPTORS, DRUG; TREATMENT OUTCOME;

EID: 84861631760     PISSN: 0334018X     EISSN: 21910251     Source Type: Journal    
DOI: 10.1515/jpem-2011-0449     Document Type: Article

References (19)

1. Aguilar-Bryan L, Bryan, J. Neonatal diabetes mellitus. Endocr Rev 2008;29:265-91.
2. Proks P, Arnold AL, Bruining J, Girard C, Flanagan SE, et al. A heterozygous activating mutation in the sulfonylurea receptor SUR1 (ABCC8) causes neonatal diabetes. Hum Mol Genet 2006;15:1793-800.
3. Patch AM, Flanagan SE, Boustred C, Hattersley AT, Ellard S. Mutations in the ABCC8 gene encoding the SUR1 subunit of the KATP channel cause transient neonatal diabetes, permanent neonatal diabetes or permanent diabetes diagnosed outside the neonatal period. Diabetes Obes Metab 2007;9(Suppl. 2):28-39.
4. Rafiq M, Flanagan SE, Patch A, Shields BM, Ellard S, et al. Effective treatment with oral sulfonylureas in patients with diabetes due to sulfonylurea receptor (SUR1) mutations. Diabetes Care 2008;31:204-9.
5. Vaxillaire M, Dechaume A, Busiah K, Cavé H, Pereira S, et al. New ABCC8 mutations in relapsing neonatal diabetes and clinical features. Diabetes 2007;56:1737-41.
6. + channel genes cause transient neonatal diabetes and permanent diabetes in childhood or adulthood. Diabetes 2007;56:1930-7.
7. Clement JP IV, Kunjilwar K, Gonzalez G, Schwanstecher M, Panten U, et al. Association and stoichiometry of K ATP channel subunits. Neuron 1997;18:827-38.
8. Shyng S-L, Nichols CG. Octameric stoichiometry of the K ATP channel complex. J Gen Physiol 1997;110:655-64.
9. + channel. FEBS Lett 1997; 409:232-6.
10. Babenko AP, Polak M, Cavé H, Busiah K, Czernichow P, et al. Activating mutations in the ABCC8 gene in neonatal diabetes mellitus. N Engl J Med 2006;355:456-66.
11. Ashcroft FM, Gribble FM. Tissue-specific effects of sulfonylureas: Lessons from studies of cloned KATP channels. J Diabetes Complications 2000;14:192-6.
12. Pearson ER, Flechtner I, Njølstad PR, Malecki MT, Flanagan SE, et al. Switching from insulin to oral sulfonylureas in patients with diabetes due to Kir6.2 mutations. N Engl J Med 2006;355:467-77.
13. Hattersley AT, Ashcroft FM. Activating mutations in Kir6.2 and neonatal diabetes: New clinical syndromes, new scientific insights, and new therapy. Diabetes 2005;54:2503-13.
14. Codner E, Flanagan S, Ellard S, Garcia H, Hattersley AT. Highdose glibenclamide can replace insulin therapy despite transitory diarrhea in early-onset diabetes caused by a novel R201L Kir6.2 mutation. Diabetes Care 2005;28:758-9.
15. Codner E, Flanagan SE, Ugarte F, García H, Vidal T, et al. Sulfonylurea treatment in young children with neonatal diabetes: Dealing with hyperglycemia, hypoglycemia, and sick days. Diabetes Care 2007;30:e28-9.
16. Malecki MT, Skupien J, Klupa T, Wanic K, Mlynarski W, et al. Transfer to sulfonylurea therapy in adult subjects with permanent neonatal diabetes due to KCNJ11-activating mutations: Evidence for improvement in insulin sensitivity. Diabetes Care 2007;30:147-9.
17. Sagen JV, Raeder H, Hathout E. Permanent neonatal diabetes due to mutations in KCNJ11 encoding Kir6.2: Patient characteristics and initial response to sulfonylurea therapy. Diabetes 2004;53:2713-8.
18. Zung A, Glaser B, Nimri R, Zadik Z. Glibenclamide treatment in permanent neonatal diabetes mellitus due to an activating mutation in Kir6.2. J Clin Endocrinol Metab 2004;89:5504-7.
19. Burke MA, Mutharasan RK, Ardehali H. The sulfonylurea receptor, an atypical ATP-binding cassette protein, and its regulation of the KATP channel. Circ Res 2008;102:164-76.